Muscular Dystrophy Clinical Trials

A listing of Muscular Dystrophy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 79 clinical trials
CMT Subtype Biomarkers and Outcome Measures

In order to prepare for clinical trials for CMT, there is ongoing work to develop more sensitive outcome measures, and there is a need for complementary biomarkers, particularly target engagement measures that can be used in clinical trials for candidate therapies. Much of this work has been focused on CMT1A, …

  • 0 views
  • 19 Feb, 2024
  • 1 location
An open label multi-cohort multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in patients with advanced T-cell lymphoma

4.0

  • 0 views
  • 19 Feb, 2024
  • 1 location
Acute Effects of Exogenous Ketone Ester Administration in Heart Failure

Please see section 1 of the full protocol

  • 0 views
  • 19 Feb, 2024
  • 1 location
An Expanded Access Program for Efgartigimod Treatment in Patients With Generalized Myasthenia Gravis

1.0

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Long-term Follow-Up Study to Evaluate the Safety and Efficacy of RGX-314

TBD

  • 0 views
  • 19 Feb, 2024
  • 1 location
Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety Tolerability and Efficacy of Efgartigimod PH20 SC in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

TBD

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Phase 2B Randomized Double-Blind Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults with Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis

A phase 2B, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of BMS-986036 in subjects with NASH and F3 fibrosis. The treatment period is 48 weeks, with drug administered as a once-weekly injection. There is also a follow-up period to assess long-term bone mineral density and immunogenicity. Target population …

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Study to Evaluate the Efficacy Safety and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin Hizentra) in Adults with Dermatomyositis (DM)

This is a phase 3, 56-week, multicenter, randomized, placebo controlled, double-blind study of IgPro20 (subcutaneous Ig) treatment in adult subjects with dermatomyositis (DM). Subjects will be randomized to 1 of 2 treatment sequences: Sequence A: 0.5 g/kg IgPro20 for 24 weeks followed by 0.5 g/kg IgPro20 for 28 weeks or …

  • 0 views
  • 19 Feb, 2024
  • 1 location
Prospective 4D Computed Tomography Angiography Of The Bicuspid Aortic Valve Apparatus: A Comparison Of Bicuspid Aortic Valves With And Without Aortic Insufficiency

The purpose of this study is to characterize the differences in the aortic valve and aortic root anatomy in patients with BAVs in order to better understand the anatomical features that allow the BAV to function normally. With this information, surgeons and cardiologists will be better able to determine which …

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects with Active Systemic Lupus Erythematosus (SLE) with Inadequate Response to Standard of Care (SOC) Therapy

Modification #2 Feb 15, 2021: Title of protocol changed and phase changed from phase 2 to phase 2b. Changes in timing of selected activities, addition of labs (ESR, coagulation tests), the PRO sub-study and a COVID related consent for remote monitoring. IB updated to Edition 5. Modification #1 May 2020: …

  • 0 views
  • 19 Feb, 2024
  • 1 location